Traitement coronavirus guide - activities

Covid: Pfizer's Covid drug Paxlovid available in pharmacies from Friday

After being granted marketing approval from the European Medicines Agency, Pfizer's Covid drug Paxlovid - 89% effective against hospitalizations and deaths caused by coronavirus - will be available from Friday February 4, 2022, in pharmacies.

Covid: Xevudy, the promising antibody therapy approved by the Haute Autorité de Santé

This Friday January 7, 2022, the Haute Autorité de Santé announced they have approved the use of Xevudy against Covid, a promising synthesized antibody therapy. The drug seems particularly effective against the Omicron variant. Here is more on the matter!

Covid: Xenothera's therapy, Xav-19, working against Omicron

And what if, amid the fight against Covid, one could rely – in addition to the upcoming vaccine – on antibody-based treatments? After Bamlanivimab – the treatment developed by the Eli Lilly laboratory – or even Regeneron, this is now French Nantes-based laboratory Xenothera’s turn to present a treatment undergoing clinical trials, Xav-19. According to primary studies, the therapy is effective against Covid's Omicron variant, but waiting for the green light for marketing from early 2022.

Coronavirus: an AstraZeneca antibody therapy approved by the Haute Autorité de Santé

This Friday December 10, the Haute Autorité de Santé announced they have approved the use of Evusheld (tixagevimab-cilgavimab), a coronavirus monoclonal antibody-based therapy developed by AstraZeneca. But the therapy includes cardiovascular risks… Here is more on the matter.

Coronavirus: the Haute Autorité de Santé does not approve emergency marketing of molnupiravir

The Haute Autorité de Santé announced - in a report issued on December 10 - they do not approve the emergency use of molnupiravir (Lafevrio) to prevent coronavirus infection. The issue goes against what the European Medicines Agency announced this past November 19, namely approving the emergency use of the drug in case of emergency.

Covid: Institut Pasteur Lille forced to stop their trials with Clofoctol

After many months of research and big hopes, the Lille Institut Pasteur has been forced to stop their clinical trials on a Clofoctol-based Covid therapy as they lack volunteering patients and financing.

Covid: Lille Institut Pasteur on a trail of a way to prevent the virus from replicating itself

And what if the Lille Institut Pasteur found a way to create a therapy that fight against coronavirus more directly? Anyway, this is what scientists from the institute say in the Angewandte Chimie magazine this past September as they found a way to prevent the virus from replicating itself in one’s organism.

Covid: EMA approved use of RoActemra (Tocilizumab) for severe disease

Is Tocilizumab – a Covid therapy – still under rolling review? The European Medicines Agency announced they have approved RoActemra (Tocilizumab) on hospitalized severe Covid patients. This anti-inflammatory therapy usually used against arthritis is able to bloc interleukin-6 and prevent cytokine storms, namely a secondary inflammation of the lungs.

Covid: vaccines and therapies available or still being reviewed

Take a stock on Covid-19 vaccines and treatments across the world. Where are the first vaccines at? Are there effective Covid-19 treatments? What are the latest discoveries and breakthroughs performed by scientists?

Covid: Sotrovimab, an antibody-based therapy developed by GSK, approved in the United Kingdom

To fight against Covid and especially the Omicron variant, the UK regulator announced this Thursday December 2 they have approved Sotrovimab, a therapy developed by the GSK laboratories based on monoclonal antibodies based on the “natural antibodies humans already make”. A therapy the European Union already ordered this past June.

Covid: Dapsone, a promising and affordable therapy under rolling review

And what if Canada just found an effective Covid therapy? Searchers from the Montreal McGill university launched in late November the 3rd phase of a clinical trial on dapsone, a therapy with anti-inflammatory properties working against cytokine storms. Its asset? Being affordable compared to the other therapies under rolling review or currently administrated, particularly expensive.

Covid: Kevzara (sarilumab) underperforming as a therapy, according to an AP-HP study

According to an AP-HP study issued this November 23, 2021, Kevzara (sarilumab) - a potential cure to Covid - does not seem to have delivered conclusive results as for its effectiveness to avoid deaths after hospitalization. The study confirms results of the clinical trial led by Sanofi who announced in September 2020 they were ending their clinical trial after results of this study were inconclusive.

Covid – AstraZeneca: conclusive results for their antibody therapy under rolling review

This Thursday November 18, 2021, AstraZeneca laboratory revealed successful clinical trials for their antibody-based Covid therapy. This therapy is said to cut risks of developing severe disease by 67%. Here is more on the matter!

Covid: what if the cure to the disease was in our genes?

And what if the cure to Covid was in our genes? This is the bet made by professor Jean-Claude Casanova from the Necker hospital in Paris and his team of international scientists. The idea: finding the gene or genes enabling to fight against the disease.

Covid: antibody cocktail Regeneron working up to eight months, the laboratory claims

Good news in the search for the fight against Covid… Regeneron announced their antibody cocktail injected in cases of severe disease was 80% effective for at least eight months, according to the drugmaker’s latest studies. It involves a cocktail of antibodies given in 2020 to U.S. President Trump when we was hospitalized for severe covid.

Covid: fluvoxamine, the antidepressant likely to cut down hospitalization risks, studies found

There is a potential new Covid drug! Following preliminary results from a Canadian study released this past August, the results of a Brazilian clinical results issued this late October in The Lancet seem to confirm antidepressant fluvoxamine considerably decreases hospitalization risk for people contaminated.

Covid: a new antibody therapy developed by Spiklmm under rolling review

Is a new Covid therapy based on monoclonal antibodies soon to be reviewed? This is what infectious disease specialist and member of Spiklmm biotech administration board Karine Lacombe has explained. The very laboratory is developing this therapy. Clinical trials are expected to start from the beginning of 2022.

Covid: Ronapreve, the preventive antibody therapy for immunocompromised people approved by the HAS

Less protected against coronavirus, immunocompromised people will be allowed to get a preventive Covid-19 therapy based on monoclonal antibodies, the Haute Autorité de Santé stated.

Covid: why is looking for a therapy more difficult than for a vaccine?

As several Covid vaccines are being given in the whole world, over 1.5 year of pandemic, the search for therapies is still groping around. Why is looking for a coronavirus therapy more difficult? Food for thoughts…

Covid: WHO to review three new therapies

Are new Covid therapies to be reviewed soon? This is what the World Health Organization or WHO announced this Wednesday August 11, 2021, stating WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs namely artesunate, imatinib and infliximab.